MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock and...
$50,000K
Proceeds from issuance of
term loan, net
$19,688K
Proceeds from
convertible grant agreement
$750K
Proceeds from exercise of
stock options
$703K
Net cash provided by
financing activities
$60,078K
Canceled cashflow
$11,063K
Net increase in
cash, cash...
$8,255K
Canceled cashflow
$51,823K
Repayment of former term
loan
$10,213K
Payments on issuance cost
from registration...
$556K
Payments from sale of
common stock and...
$167K
Payment of loan
financing cost
$127K
Stock-based compensation
expense
$8,108K
Non-cashlease expense
$774K
Non-cash interest
expense related to term...
$729K
Loss on debt
extinguishment
-$681K
Depreciation
$661K
Other
$327K
Accounts payable
$221K
Loss on disposal of
assets
-$156K
Prepaid expenses and
other assets
-$101K
Net cash used in
operating activities
-$51,769K
Effect of exchange rate
changes on cash, cash...
-$30K
Net cash used in
investing activities
-$24K
Canceled cashflow
$11,758K
Net loss
-$63,238K
Capital expenditures
$24K
Accrued liabilities and
other liabilities
-$289K
Back
Back
Cash Flow
source: myfinsight.com
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)